University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Charalambos (Babis) Andreadis, M.D.

Blood disorder specialist

Dr. Charalambos (Babis) Andreadis specializes in adult bone marrow transplantation (BMT) and the treatment of Hodgkin's and non-Hodgkin's lymphoma, leukemia and multiple myeloma. He is certified by the American Board of Internal Medicine in hematology, medical oncology and internal medicine. His research, published widely in medical and scientific journals, addresses the clinical and genetic determinants of response to therapy and toxicity, and patient outcomes in these disorders.

Andreadis earned a medical degree at Columbia University's College of Physicians and Surgeons and was elected to Alpha Omega Alpha in 1998. He completed a residency in medicine at the New York-Presbyterian Hospital and a fellowship in the division of hematology and oncology at the Hospital of the University of Pennsylvania, where he joined the faculty in 2004. Andreadis earned a master's degree in clinical epidemiology, with a focus on pharmacogenetics, at the University of Pennsylvania. He is an assistant clinical professor of medicine at UCSF and a member of the UCSF Helen Diller Family Comprehensive Cancer Center.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Conditions & Treatments

More about Charalambos (Babis) Andreadis

Additional Languages

Greek
Spanish

Education

Columbia University College of Physicians and Surgeons 1998

Residencies

Columbia Presbyterian Medical Center, Internal Medicine 2001

Fellowships

University of Pennsylvania, Hematology-Oncology 2004

Selected Research and Publications

  1. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
  2. Olin RL, Andreadis C. David versus Goliath: decision analysis predicts results of a large clinical trial in follicular lymphoma. J Clin Oncol. 2013 Oct 1; 31(28):3608-9.
  3. Yee SW, Mefford JA, Singh N, Percival ME, Stecula A, Yang K, Witte JS, Takahashi A, Kubo M, Matsuda K, Giacomini KM, Andreadis C. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet. 2013 Jun; 58(6):353-61.
  4. Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol. 2010 Apr; 85(4):255-60.
  5. Pincus LB, Zehnder JL, Neuhaus IM, Andreadis C, McCalmont TH. Presentation of extranodal natural killer T-cell lymphoma, nasal type, with poorly circumscribed erythematous patches. J Clin Oncol. 2010 Feb 20; 28(6):e94-5.
  6. Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1; 14(17):5619-25.
  7. Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Am J Hematol. 2007 Dec; 82(12):1071-5.
  8. Mato AR, Morgans AK, Roullet MR, Bagg A, Glatstein E, Litt HI, Downs LH, Chong EA, Olson ER, Andreadis C, Schuster SJ. Primary cardiac lymphoma: utility of multimodality imaging in diagnosis and management. Cancer Biol Ther. 2007 Dec; 6(12):1867-70.
  9. Ahya VN, Douglas LP, Andreadis C, Arnoldi S, Svoboda J, Kotloff RM, Hadjiliadis D, Sager JS, Woo YJ, Pochettino A, Schuster SJ, Stadtmauer EA, Tsai DE. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant. 2007 Aug; 26(8):839-44.
  10. Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 2007 Apr 15; 109(8):3409-16.
  11. Frey NV, Svoboda J, Andreadis C, Tsai DE, Schuster SJ, Elstrom R, Rubin SC, Nasta SD. Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature. Leuk Lymphoma. 2006 Sep; 47(9):1894-901.
  12. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, Alavi A. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Commun. 2006 Jan; 27(1):11-5.
  13. Papageorgiou A, Andreadis C, Boutis A, Lialiaris TS, Mouratidou D. NSC 290205-based therapy in murine pancreatic adenocarcinoma PAN02 in combination with adriamycin (ADR). Anticancer Res. 2006 Jan-Feb; 26(1A):243-7.
  14. Svoboda J, Andreadis C, Downs LH, Miller Jr WT, Tsai DE, Schuster SJ. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma. 2005 Sep; 46(9):1365-8.
  15. Chong EA, Svoboda J, Cherian S, Andreadis C, Downs LH, Zhuang H, Alavi A, Tsai DE, Schuster SJ. Regression of pulmonary MALT lymphoma after treatment with rituximab. Leuk Lymphoma. 2005 Sep; 46(9):1383-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.